LOG IN
SIGN UP
News
SANA
3.250
-0.61%
-0.020
BRIEF-Sana Biotechnology Reports Fourth Quarter And Full Year 2022 Financial Results
Reuters · 6d ago
Sana Biotechnology Non-GAAP EPS of -$0.40 beats by $0.01
Seeking Alpha · 6d ago
Sana Biotechnology Q4 EPS $(0.40) Beats $(0.51) Estimate
Benzinga · 03/16 20:17
Sana Biotechnology: Burning Cash, Going Nowhere Fast
Seeking Alpha · 02/22 22:23
Insider Buy: Sana Biotechnology
Insider Buy: Sana Biotechnology
MT Newswires · 02/17 17:32
ANALYSIS-Biotech IPOs to bloom with spotlight on startups with human trial data
NASDAQ · 02/13 13:54
Sana Biotechnology: Time And Cash Burn Are The Enemies
Seeking Alpha · 02/08 16:21
Sana Biotechnology A Buy On Low Price And First IND
Seeking Alpha · 02/08 14:35
Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update
Seeking Alpha · 01/30 05:27
BRIEF-Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies
Reuters · 01/26 22:29
Sana Biotechnology gains FDA IND clearance for CAR T therapy for B-cell malignancies
Seeking Alpha · 01/26 21:43
Sana Biotechnology Says FDA Clears Investigational New Drug Application for SC291 Therapy Study
Sana Biotechnology Says FDA Clears Investigational New Drug Application for SC291 Therapy Study
MT Newswires · 01/26 17:46
Morgan Stanley Remains a Buy on Sana Biotechnology (SANA)
TipRanks · 01/24 16:26
--Morgan Stanley Adjusts Price Target on Sana Biotechnology to $13 From $15, Maintains Overweight Rating
--Morgan Stanley Adjusts Price Target on Sana Biotechnology to $13 From $15, Maintains Overweight Rating
MT Newswires · 01/24 10:45
Sana Biotechnology Highlighted Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at ASH 2022
Benzinga · 12/12/2022 01:18
BRIEF-Sana Biotechnology Highlights Hypoimmune Allogeneic Car T Cell Programs And In Vivo Technology Platform
Reuters · 12/11/2022 23:01
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems Allogeneic HIP CAR T cells can be produced with no...
GlobeNewswire · 12/11/2022 22:30
Sana Biotechnology to lay off 15% of its employees
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is laying off about 15% of its staff, according to a Nov. 29 Securities and Exchange Commission filing. The biotech said it was stopping further investment in SC187, its program aimed at heart failure. ...
American City Business Journals · 12/01/2022 05:11
Once valued at $6 billion, Sana Biotechnology plans to cut 15% of workforce
The company earlier this year decided to shift manufacturing from Fremont to near its Seattle headquarters.
American City Business Journals · 11/30/2022 15:55
Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce
Benzinga · 11/30/2022 13:43
More
Webull provides a variety of real-time SANA stock news. You can receive the latest news about Sana Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SANA
Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The Company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).